Yellowbird Diagnostics develops plug-and-play imaging dyes for medical procedures, including PET radiotracers and MRI dye platforms. These advanced agents provide molecular information about disease, enabling earlier and more effective diagnostic decisions for conditions affecting the brain, heart, and kidneys. The company's technology reveals disease hallmarks that are otherwise invisible, improving diagnostic clarity across various clinical workflows.
Funding
$370K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FFounders
Product
Problem
Current PET and MRI procedures often lack the sensitivity to detect early-stage diseases affecting the brain, heart, and kidneys. Existing imaging agents may not reveal subtle molecular changes indicative of disease onset, leading to delayed or inaccurate diagnoses. Some MRI dyes also carry risks that prevent their use in certain patient populations.
Solution
Yellowbird Diagnostics develops a suite of advanced imaging dyes designed to enhance the accuracy and early detection of diseases. Their "plug-and-play" dyes integrate into existing PET and MRI workflows, providing clinicians with molecular-level insights into disease processes. The company's dyes are designed to reveal previously invisible hallmarks of disease, empowering earlier and more effective medical decisions. Yellowbird's technology aims to improve diagnostic imaging for patients with diseases of the brain, heart, and kidneys.
Target Audience
The primary target audience includes clinicians and medical professionals specializing in cardiology, neurology, and nephrology, as well as hospitals and imaging centers seeking to improve diagnostic accuracy and early disease detection.
Features
- **NeuCaVis™:** A PET dye designed for improved identification of heart and brain diseases compared to current clinical standards.
- **FilTrak™:** A metal-free MRI dye platform capable of mapping kidney function in patients who are typically excluded from MRI scans due to risks associated with existing dyes.
- **Aurogami™:** A nanomaterial-based dye platform for identifying previously invisible markers of cardiac and vascular inflammation using interventional cardiology workflows.